{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:45:29Z","timestamp":1778946329756,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.neuropharm.2011.11.016","type":"journal-article","created":{"date-parts":[[2011,12,11]],"date-time":"2011-12-11T07:55:02Z","timestamp":1323590102000},"page":"1700-1707","source":"Crossref","is-referenced-by-count":25,"title":["Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model"],"prefix":"10.1016","volume":"62","author":[{"given":"Peternella S.","family":"Verhave","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjan J.","family":"Jongsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland M.","family":"Van Den Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond A.P.","family":"Vanwersch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"August B.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid H.C.H.M.","family":"Philippens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2011.11.016_bib1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0006-8993(01)02944-4","article-title":"Neuroprotective effect of riluzole in MPTP-treated mice","volume":"918","author":"Araki","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0306-4522(96)00249-7","article-title":"Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat","volume":"74","author":"Barneoud","year":"1996","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2011.11.016_bib3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0014-2999(95)00362-O","article-title":"Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study","volume":"284","author":"Benazzouz","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A\u00a0controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group","volume":"330","author":"Bensimon","year":"1994","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000113682","article-title":"Biomarkers for the early detection of Parkinson's and Alzheimer's disease","volume":"5","author":"Berg","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib6","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0028-3908(99)00188-4","article-title":"The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation","volume":"39","author":"Boireau","year":"2000","journal-title":"Neuropharmacology"},{"issue":"7343","key":"10.1016\/j.neuropharm.2011.11.016_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nature09788","article-title":"Caspase signalling controls microglia activation and neurotoxicity","volume":"472","author":"Burguillos","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.neuropharm.2011.11.016_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11481-011-9280-9","article-title":"Activated immune cells in Parkinson's disease","volume":"6","author":"Cao","year":"2011","journal-title":"J.\u00a0Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib9","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0028-3908(98)00081-1","article-title":"Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons","volume":"37","author":"Centonze","year":"1998","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2011.11.016_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tins.2009.01.006","article-title":"Calcium homeostasis, selective vulnerability and Parkinson's disease","volume":"32","author":"Chan","year":"2009","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib11","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1471-4159.2007.05067.x","article-title":"Differential interaction of NMDA receptor subtypes with the post-synaptic density-95 family of membrane associated guanylate kinase proteins","volume":"104","author":"Cousins","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00702-004-0206-z","article-title":"Effects of riluzole on combined MPTP\u00a0+\u00a03-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice","volume":"112","author":"Diguet","year":"2005","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib13","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1212\/WNL.47.6_Suppl_4.233S","article-title":"The pharmacology and mechanism of action of riluzole","volume":"47","author":"Doble","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2011.11.016_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1749-6632.2003.tb07488.x","article-title":"Is the initial insult in Parkinson's disease and dementia with lewy bodies a neuritic dystrophy?","volume":"991","author":"Duda","year":"2003","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.neuropharm.2011.11.016_bib15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1523\/JNEUROSCI.13-03-01065.1993","article-title":"Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation","volume":"13","author":"Edgar","year":"1993","journal-title":"J.\u00a0Neurosci."},{"issue":"Pt 5","key":"10.1016\/j.neuropharm.2011.11.016_bib16","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson's disease: substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2011.11.016_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1749-6632.2003.tb07469.x","article-title":"Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease","volume":"991","author":"Fiskum","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.expneurol.2005.11.010","article-title":"Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease","volume":"198","author":"Fumagalli","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1212\/WNL.59.4.585","article-title":"REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease","volume":"59","author":"Gagnon","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2011.11.016_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1042\/bss0660085","article-title":"Mitochondrial dysfunction in Parkinson's disease","volume":"66","author":"Greenamyre","year":"1999","journal-title":"Biochem. Soc. Symp."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1476-5381.1994.tb16203.x","article-title":"Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action","volume":"113","author":"Hubert","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib22","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1213\/01.ane.0000263267.04198.36","article-title":"Riluzole, a glutamate release inhibitor, induces loss of righting reflex, antinociception, and immobility in response to noxious stimulation in mice","volume":"104","author":"Irifune","year":"2007","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1353-8020(01)00040-2","article-title":"A\u00a0double-blind, placebo-controlled and longitudinal study of riluzole early Parkinson's disease","volume":"8","author":"Jankovic","year":"2002","journal-title":"Parkinsonism Relat. Disord."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2011.11.016_bib24","first-page":"S16","article-title":"Functional models of Parkinson's disease: a valuable tool in the development of novel therapies","volume":"64","author":"Jenner","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib25","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1111\/j.1460-9568.2008.06211.x","article-title":"Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in\u00a0vitro","volume":"27","author":"Lamanauskas","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.nurt.2008.01.007","article-title":"Protection against Parkinson's disease progression: clinical experience","volume":"5","author":"LeWitt","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2011.11.016_bib27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/147323000903700221","article-title":"Axonal degeneration of nigra-striatum dopaminergic neurons induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice","volume":"37","author":"Li","year":"2009","journal-title":"J.\u00a0Int. Med. Res."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/00023210-200317100-00004","article-title":"Neuroprotective strategies in Parkinson's disease: an update on progress","volume":"17","author":"Mandel","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2011.11.016_bib29","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1358\/dot.1997.33.8.446334","article-title":"Pharmacokinetics and metabolism of riluzole","volume":"33","author":"Martinet","year":"1997","journal-title":"Drugs Today"},{"key":"10.1016\/j.neuropharm.2011.11.016_bib30","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/mds.21751","article-title":"Glial reactions in Parkinson's disease","volume":"23","author":"McGeer","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1196\/annals.1427.002","article-title":"Oxidative stress and energy crises in neuronal dysfunction","volume":"1147","author":"Nicholls","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.neuropharm.2011.11.016_bib32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1006\/nbdi.2000.0297","article-title":"A\u00a0novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C","volume":"7","author":"Noh","year":"2000","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/mds.1272","article-title":"Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence","volume":"17","author":"Obinu","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10863-007-9123-9","article-title":"Transport ATPases into the year 2008: a brief overview related to types, structures, functions and roles in health and disease","volume":"39","author":"Pedersen","year":"2007","journal-title":"J.\u00a0Bioenerg. Biomembr."},{"issue":"23\u201324","key":"10.1016\/j.neuropharm.2011.11.016_bib35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.drudis.2010.08.009","article-title":"The marmoset model of Parkinsonism: a multipurpose non-human primate model for neurodegenerative diseases","volume":"15","author":"Philippens","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuropharm.2011.11.016_bib36","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0022-3565(24)36856-9","article-title":"Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels","volume":"282","author":"Song","year":"1997","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"Suppl. 4","key":"10.1016\/j.neuropharm.2011.11.016_bib37","first-page":"IV2","article-title":"Early diagnosis of Parkinson's disease","volume":"253","author":"Spiegel","year":"2006","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib38","series-title":"The Brain of the Common Marmoset: Callithrix jacchus","author":"Stephan","year":"1980"},{"key":"10.1016\/j.neuropharm.2011.11.016_bib39","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1046\/j.1471-4159.2000.0752259.x","article-title":"Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism","volume":"75","author":"Storch","year":"2000","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0304-3940(88)90125-5","article-title":"Riluzole, a glutamate antagonist, enhances slow wave and REM sleep in rats","volume":"88","author":"Stutzmann","year":"1988","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2011.11.016_bib41","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1212\/WNL.0b013e318198db11","article-title":"Diagnosis and the premotor phase of Parkinson disease","volume":"72","author":"Tolosa","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2011.11.016_bib42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00213-006-0340-4","article-title":"Behavioral effects of modafinil in marmoset monkeys","volume":"185","author":"van Vliet","year":"2006","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2011.11.016_bib43","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bbr.2009.01.022","article-title":"Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease","volume":"200","author":"Verhave","year":"2009","journal-title":"Behav. Brain Res."},{"issue":"8","key":"10.1016\/j.neuropharm.2011.11.016_bib45","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.5665\/SLEEP.1174","article-title":"REM Sleep Behavior Disorder in the Marmoset MPTP Model of Early Parkinson Disease","volume":"34","author":"Verhave","year":"2011","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2011.11.016_bib44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuroscience.2004.01.019","article-title":"Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes)","volume":"125","author":"Wang","year":"2004","journal-title":"Neuroscience"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390811004953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390811004953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T12:40:35Z","timestamp":1742042435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390811004953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0028390811004953"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2011.11.016","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}